VICTORIA, BC, Sept. 8, 2020 /CNW/ - IMMUNOPRECISE
ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF)
(FSE:TQB2), a leader in full-service, therapeutic antibody
discovery and development, today announced that Dr. Jennifer Bath, CEO of IPA, will participate on a
virtual panel, entitled, "New Approaches to COVID-19: Hidden
Breakthroughs," being held on Thursday,
September 10, 2020 at 1:00 p.m.
ET.
The virtual panel discussion will also include: Tom Equels, CEO of AIM ImmunoTech
Inc. (NYSE American: AIM); Dr. David
Jin, CEO of Avalon GlobloCare Corp. (NASDAQ:AVCO);
Jeff Wolf, CEO of Heat Biologics,
Inc. (NASDAQ: HTBX) and Vered
Caplan, CEO of Orgenesis Inc. (NASDAQ: ORGS).
The event brings together executives from leading
biopharmaceutical companies to discuss how their companies are
helping address the COVID-19 pandemic. The panel will be moderated
by broadcast journalist Christine
Corrado of Proactive Investors. Investors interested in
attending the event can register at:
https://zoom.us/webinar/register/8215990551540/WN_YFe8n6dQSm6mpgG3iWfF-w
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is
a global technology platform company with end-to-end solutions
empowering companies to discover and develop therapies against any
disease. The Company's experience and cutting-edge technologies
enable unparalleled support of its partners in their quest to bring
innovative treatments to the clinic. ImmunoPrecise's full-service
capabilities dramatically reduce the time required for, and the
inherent risk associated with, conventional multi-vendor product
development. For further information,
visit www.immunoprecise.com or
contact solutions@immunoprecise.com.
Forward Looking Information
This news release
contains statements that, to the extent they are not recitations of
historical fact, may constitute "forward-looking statements" within
the meaning of applicable Canadian securities laws. The Company
uses words such as "may", "would", "could", "will", "likely",
"expect", "believe", "intend", "should" and similar expressions to
identify forward-looking statements and include the Company's
beliefs with respect to the potential for its antibodies to be
further developed or approved to treat COVID-19 (or SARS-CoV-2)
or to complete any transactions with respect to those
antibodies. Any such forward-looking statements are based on
assumptions and analyses made by ImmunoPrecise in light of its
experience and its perception of historical trends, current
conditions and expected future developments. However, whether
actual results and developments will conform to ImmunoPrecise's
expectations and predictions is subject to any number of risks,
assumptions and uncertainties. Many factors could cause
ImmunoPrecise's actual results to differ materially from those
expressed or implied by the forward-looking statements contained in
this news release. Such factors include, among other things, actual
revenues and earnings for IPA being lower than anticipated, and
those risks and uncertainties described in ImmunoPrecise's annual
management discussion and analysis for the previous quarter ended
January 31, 2020 which can be
accessed at www.sedar.com. The "forward-looking
statements" contained herein speak only as of the date of this
press release and, unless required by applicable law, ImmunoPrecise
undertakes no obligation to publicly update or revise such
information, whether as a result of new information, future events
or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE ImmunoPrecise Antibodies Ltd.